| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
Inovio Pharmaceuticals Inc (F: GBMB)
GBMB Technical Analysis
5
| As on 26th Mar 2024 GBMB STOCK Price closed @ 11.94 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 1.05 & Strong Buy for SHORT-TERM with Stoploss of 1.85 we also expect STOCK to react on Following IMPORTANT LEVELS. |
GBMBSTOCK Price
| Open | 11.34 | Change | Price | % |
| High | 11.94 | 1 Day | 0.86 | 7.76 |
| Low | 11.34 | 1 Week | 2.09 | 21.22 |
| Close | 11.94 | 1 Month | 5.25 | 78.48 |
| Volume | 54 | 1 Year | 10.07 | 538.50 |
| 52 Week High 11.04 | 52 Week Low 0.31 | ||||
F Germany Most Active Stocks
| IMU | 0.10 | -99.65% |
| IMU | 0.10 | -99.65% |
| IMU | 0.10 | -99.65% |
| IMU | 0.10 | -99.65% |
| IMU | 0.10 | -99.65% |
| ENB | 47.60 | -0.92% |
| TEF | 3.84 | -0.52% |
| TEF | 3.84 | -0.52% |
| WHL | 5150.00 | -0.44% |
| WDI | 0.05 | -37.50% |
F Germany Top Gainers Stocks
F Germany Top Losers Stocks
| GBMB Daily Charts |
GBMB Intraday Charts |
Whats New @ Bazaartrend |
GBMB Free Analysis |
|
|
GBMB Important Levels Intraday
| RESISTANCE | 13.10 |
| RESISTANCE | 12.73 |
| RESISTANCE | 12.50 |
| RESISTANCE | 12.27 |
| SUPPORT | 11.61 |
| SUPPORT | 11.38 |
| SUPPORT | 11.15 |
| SUPPORT | 10.78 |
GBMB Forecast May 2025
| 4th UP Forecast | 13.52 |
| 3rd UP Forecast | 13.01 |
| 2nd UP Forecast | 12.7 |
| 1st UP Forecast | 12.39 |
| 1st DOWN Forecast | 11.49 |
| 2nd DOWN Forecast | 11.18 |
| 3rd DOWN Forecast | 10.87 |
| 4th DOWN Forecast | 10.36 |
GBMB Weekly Forecast
| 4th UP Forecast | 12.77 |
| 3rd UP Forecast | 12.50 |
| 2nd UP Forecast | 12.34 |
| 1st UP Forecast | 12.17 |
| 1st DOWN Forecast | 11.71 |
| 2nd DOWN Forecast | 11.54 |
| 3rd DOWN Forecast | 11.38 |
| 4th DOWN Forecast | 11.11 |
GBMB Forecast2025
| 4th UP Forecast | 34.35 |
| 3rd UP Forecast | 27.16 |
| 2nd UP Forecast | 22.72 |
| 1st UP Forecast | 18.28 |
| 1st DOWN Forecast | 5.6 |
| 2nd DOWN Forecast | 1.16 |
| 3rd DOWN Forecast | -3.28 |
| 4th DOWN Forecast | -10.47 |
Inovio Pharmaceuticals Inc ( F Germany Symbol : GBMB )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
GBMB Business Profile
Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon optimized plasmids that have ability to help break the immune system's tolerance of cancerous or infected cells and facilitate cross-strain protection against unmatched and matched pathogen variants. The company is involved in conducting and planning clinical studies of its DNA medicines for HPV-associated precancers, including cervical, vulvar, and anal dysplasia; HPV-associated cancers, including head and neck, cervical, anal, penile, vulvar, and vaginal; other HPV-associated disorders, such as recurrent respiratory papillomatosis; glioblastoma multiforme; prostate cancer; HIV; Ebola; Middle East Respiratory Syndrome (MERS); Lassa fever; Zika virus; and the COVID-19 virus (coronavirus). Its partners and collaborators include ApolloBio Corp., AstraZeneca, Beijing Advaccine Biotechnology Co., Ltd., The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations (CEPI), Defense Advanced Research Projects Agency (DARPA), HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, Medical CBRN Defense Consortium (MCDC), National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Ology Bioservices, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron, Thermo Fisher Scientific, University of Pennsylvania, Walter Reed Army Institute of Research, and The Wistar Institute. The company also has an agreement with Richter-Helm BioLogics GmbH & Co. KG to support investigational DNA vaccine INO-4800, which is currently in Phase I clinical testing for COVID-19; and a partnership with International Vaccine Institute and Seoul National University Hospital. The company was founded in 1979 and is headquart Address: 660 West Germantown Pike, Plymouth Meeting, PA, United States, 19462
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service